Hepatitis C viremia and genotype distribution among a sample of nonmedical prescription drug users exposed to HCV in rural Appalachia

Journal of Medical Virology

Volumn 84, Issue 9, 2012, Pages 1376-1387

  Young, April M ^a,b   Crosby, Richard A ^c   Oser, Carrie B ^b,d   Leukefeld, Carl G ^b   Stephens, Dustin B ^b   Havens, Jennifer R ^b  

^a EMORY UNIVERSITY   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF KENTUCKY COLLEGE OF PUBLIC HEALTH   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Genotype; Hepatitis C virus; Injection drug use; Rural

Indexed keywords

BOCEPREVIR; NON PRESCRIPTION DRUG; TELAPREVIR; VIRUS RNA;

ADULT; ARTICLE; DEMOGRAPHY; DRUG RESPONSE; DRUG USE; FEMALE; GENOTYPE; HEALTH CARE COST; HEPATITIS C; HIGH RISK BEHAVIOR; HUMAN; LIVER CELL CARCINOMA; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; POPULATION; PREVALENCE; VIREMIA; VIRUS LOAD;

ADULT; APPALACHIAN REGION; DRUG USERS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; KENTUCKY; MALE; MIDDLE AGED; NEEDLE SHARING; OPIOID-RELATED DISORDERS; PREVALENCE; RNA, VIRAL; RURAL POPULATION; VIREMIA;

HEPATITIS C VIRUS;

EID: 84864145341     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.23252     Document Type: Article

References (131)

1. Alberti A. 1999. Interferon Alfacon-1: A novel interferon for the treatment of chronic hepatitis C. Biodrugs 12: 343-357.
2. Appalachian Regional Commission. 2011. Economic Overview of Appalachia 2010. Regional Planning and Research Division.
3. Armstrong GL, Wasley A, Simard EP, McQuillan GM, Kuhnert WL, Alter MJ. 2006. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 144: 705-714.
4. Asselah T, Estrabaud E, Bieche I, Lapalus M, De Muynck S, Vidaud M, Saadoun D, Soumelis V, Marcellin P. 2010. Hepatitis C: Viral and host factors associated with non-response to pegylated interferon plus ribavirin. Liver Int 30: 1259-1269.
5. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, Zeuzum S, Poordad F, Goodman ZD, Sings HL, Boparai N, Burroughs M, Brass CA, Albrecht JK, Esteban R. 2011. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364: 1207-1217.
6. Bell SE. 2009. There ain't no bond in town like there used to be: The destruction of social capital in the West Virginia coalfields. Sociol Forum 24: 631-657.
7. Berger A, von Depka Prondzinski M, Doerr H, Rabenau H, Weber B. 1996. Hepatitis C plasma viral load is associated with HCV genotype but not with HIV coinfection. J Med Virol 48: 339-343.
8. Bernstein D, Kleinman N, Barker C, Revicki D, Green J. 2002. Relationship of health-related quality of life to treatment adherence and sustained response in chronic hepatitis C patients. Hepatology 35: 704-708.
9. Blatt LM, Mutchnick MG, Tong MJ, Klion FM, Lebovics E, Freilich B, Bach N, Smith C, Herrera J, Tobias H, Conrad A, Schmid P, McHutchison JG. 2000. Assessment of hepatitis C virus RNA and genotype from 6807 patients with chronic hepatitis C in the United States. J Viral Hepat 7: 196-202.
10. Boodram B, Herschow R, Cotler S, Ouellet L. 2011. Chronic hepatitis C virus infection and increases in viral load in a prospective cohort of young, HIV-uninfected injection drug users. Drug Alcohol Depend 119: 166-171.
11. Brechot C. 1997. Hepatitis C virus 1b, cirrhosis, and hepatocellular carcinoma. Hepatology 25: 772-774.
12. Bruno S, Silini E, Crosignani A, Borzio F, Leandro G, Bono F, Asti M, Rossi S, Larghi A, Cerino A, Podda M, Mondelli MU. 1997. Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study. Hepatology 25: 754-758.
13. Bruno S, Crosignani A, Maisonneuve P, Rossi S, Silini E, Mondelli MU. 2007. Hepatitis C virus genotype 1b as a major risk factor associated with hepatocellular carcinoma in patients with cirrhosis: A seventeen-year prospective cohort study. Hepatology 46: 1350-1356.
14. Centers for Disease Control and Prevention. 2005. Update: Syringe exchange programs-United States, 2002. MMWR 54: 673-676.
15. Chlabicz S, Flisiak R, Kowalczuk O, Grzeszczuk A, Pytel-Krolczuk B, Prokopowicz D, Chyczewski L. 2008. Changing HCV genotypes distribution in Poland-Relation to source and time of infection. J Clin Virol 42: 156-159.
16. Colombo M. 1999. Hepatitis C virus and hepatocellular carcinoma. Best Pract Res Clin Gastroenterol 13: 519-528.
17. Daniels D, Grytdal S, Wasley A. 2009. Surveillance for acute viral hepatitis-United States, 2007. MMWR Surveill Summ 58: 1-27.
18. Davis K, Mitra D, Medjedovic J, Beam C, Rustgi VK. 2011. Direct economic burden of chronic hepatitis C virus in a United States managed care population. J Clin Gastroenterol 45: 17-24.
19. Drug Enforcement Administration (March 2002). Drug Intelligence Brief, OxyContin: Pharmaceutical Diversion.
20. Des Jarlais DC, Perlis T, Arasteh K, Torian LV, Hagan H, Beatrice S, Smith L, Wethers J, Milliken J, Mildvan D, Yancovitz S, Friedman SR. 2005. Reductions in hepatitis C virus and HIV infections among injecting drug users in New York City 1990-2001. AIDS 19: S20-S25.
21. Des Jarlais DC, McKnight C, Goldblatt C, Purchase D. 2009. Doing harm reduction better: Syringe exchange in the United States. Addiction 104: 1441-1446.
22. Di Bisceglie AM. 1997. Hepatitis C and hepatocellular carcinoma. Hepatology 26: 34S-38S.
23. Di Tommaso L, Macchia S, Morandi L, Leoncini S, Pession A, Dal Monte PR, Foschini MP. 2003. Correlation between histologic staging, hepatitis C virus genotypes and clinical features in HCV chronic hepatitis: evidence of a new pattern. Int J Surg Pathol 11: 197-204.
24. DiBonaventura M, Wagner J, Yuan Y, L'Italien G, Langley P, Ray Kim W. 2010. Humanistic and economic impacts of hepatitis C infection in the United States. J Med Econ 13: 709-718.
25. Dore GJ, Hellard M, Matthews GV, Grebely J, Haber PS, Petoumenos K, Yeung B, Marks P, van Beek I, McCaughan G, White P, French R, Rawlinson W, Lloyd AR, Kaldor JM, Australian Trial in Acute Hepatitis C Study Group. 2010. Effective treatment of injecting drug users with recently acquired hepatitis C virus infection. Gastroenterology 138: 123-135.
26. Dore GJ, Matthews GV, Rockstroh J. 2011. Future of hepatitis C therapy: Development of direct-acting antivirals. Curr Opin HIV AIDS 6: 508-513.
27. El-Serag HB, Mason AC. 2000. Risk factors for the rising rates of primary liver cancer in the United States. Arch Intern Med 160: 3227-3230.
28. Fattovich G, Stroffolini T, Zagni I, Donato F. 2004. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 127: S35-S50.
29. Fonseca-Coronado S, Escobar-Gutierrez A, Ruiz-Tovar K, Cruz-Rivera MY, Rivera-Osorio P, Vazquez-Pichardo M, Carpio-Pedroza JC, Ruiz-Pacheco JA, Cazares F, Vaughan G. 2012. Specific detection of naturally occurring telaprevir and boceprevir (protease inhibitors) HCV resistant mutants among treatment naive infected individuals. J Clin Microbiol 50: 281-287.
30. Foster G, Goldin R, Thomas H. 1998. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology 27: 209-212.
31. Fried MW. 2011. The role of triple therapy in HCV genotype 1-experienced patients. Liv Int 31: 58-61.
32. Garfein RS, Golub ET, Greenberg AE, Hagan H, Hanson DL, Hudson SM, Kapadia F, Latka MH, Ouellet LJ, Purcell DW, Strathdee SA, Thiede H. 2007. A peer-education intervention to reduce injection risk behaviors for HIV and hepatitis C virus infection in young injection drug users. AIDS 21: 1923-1932.
33. Gérard C, Delwaide J, Vaira D, Bastens B, Servais B, Wain E, Bataille C, Daenen G, Belaïche J. 2005. Evolution over a 10 year period of the epidemiological profile of 1, 726 newly diagnosed HCV patients in Belgium. J Med Virol 76: 503-510.
34. Grant WC, Jhaveri RR, McHutchison JG, Schulman KA, Kauf TL. 2005. Trends in health care resource use for hepatitis C virus infection in the United States. Hepatology 42: 1406-1413.
35. Grebely J, Genoway KA, Raffa JD, Dhadwal G, Rajan T, Showler G, Kalousek K, Duncan F, Tyndall MW, Fraser C, Conway B, Fischer B. 2008. Barriers associated with the treatment of hepatitis C virus infection among illicit drug users. Drug Alcohol Depend 93: 141-147.
36. Grebely J, Knight E, Ngai T, Genoway KA, Raffa JD, Storms M, Gallagher L, Krajden M, Dore GJ, Duncan F, Conway B. 2010. Reinfection with hepatitis C virus following sustained virological response in injection drug users. J Gastroenterol Hepatol 25: 1281-1284.
37. Hagan H, Thiede H, Weiss NS, Hopkins SG, Duchin JS, Alexander ER. 2001. Sharing of drug preparation equipment as a risk factor for hepatitis C. Am J Public Health 91: 42-46.
38. Han CJ, Lee HS, Kim HS, Choe JH, Kim CY. 1997. Hepatitis C virus genotypes in Korea and their relationship to clinical outcome in type C chronic liver diseases. Korean J Intern Med 12: 21-27.
39. Hartwell D, Jones J, Baxter L, Shepherd J. 2011. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: A systematic review and economic evaluation. Health Technol Assess 15: 1-210.
40. Havens JR, Oser CB, Leukefeld CG, Webster J, Martin S, O'Connell D, Surratt H, Inciardi J. 2007. Differences in prevalence of prescription opiate misuse among rural and urban probationers. Am J Drug Alcohol Abuse 33: 309-317.
41. Haydon GH, Jarvis LM, Simmonds P, Harrison DJ, Garden OJ, Hayes PC. 1997. Association between chronic hepatitis C infection and hepatocellular carcinoma in a Scottish population. Gut 40: 128-132.
42. Heckathorn D. 1997. Respondent-driven sampling: A new approach to the study of hidden populations. Soc Probl 44: 174-179.
43. Heckathorn D. 2002. Respondent-driven sampling II: Deriving valid population estimates from chain-referral samples of hidden populations. Soc Probl 49: 11-34.
44. Hellard M, Sacks-Davis R, Gold J. 2009. Hepatitis C treatment for injection drug users: a review of the available evidence. Clin Infect Dis 49: 561-573.
45. Hisada M, Chatterjee N, Kalaylioglu Z, Battjes RJ, Goedert JJ. 2005. Hepatitis C virus load and survival among injection drug users in the United States. Hepatology 42: 1446-1452.
46. Katsoulidou A, Sypsa V, Tassopoulos NC, Boletis J, Karafoulidou A, Ketikoglou I, Tsantoulas D, Vafiadi I, Hatzis G, Skoutelis A, Akriviadis E, Vasiliadis T, Kitis G, Magiorkinis G, Hatzakis A. 2006. Molecular epidemiology of hepatitis C virus (HCV) in Greece: temporal trends in HCV genotype-specific incidence and molecular characterization of genotype 4 isolates. J Viral Hepat 13: 19-27.
47. Khalid O, Bacon BR. 2011. Management of the treatment-experienced patient infected with hepatitis C virus genotype 1: options and considerations. Clin Liver Dis 15: 573-583.
48. Khan A, Tanaka Y, Azam Z, Abbas Z, Kurbanov F, Saleem U, Hamid S, Jafri W, Mizokami M. 2009. Epidemic spread of hepatitis C virus genotype 3a and relation to high incidence of hepatocellular carcinoma in Pakistan. J Med Virol 81: 1189-1197.
49. Kentucky Legislative Research Commission. 1992. Definitions for KRS 218A.500 and 218A.510-unlawful practices-penalties, KRS 218A.500(1992). Accessed on February 6, 2011 at
50. Kentucky Legislative Research Commission. 2005. Sale and disposal of hypodermic syringes or needles, KRS 217.177(2005). Accessed on February 6, 2011 at
51. Kobayashi M, Tanaka E, Sodeyama T, Urushihara A, Matsumoto A, Kiyosawa K. 1996. The natural course of chronic hepatitis C: A comparison between patients with genotypes 1 and 2 hepatitis C viruses. Hepatology 23: 695-699.
52. Lam N. 1999. Clinical review. Hepatitis C: natural history, diagnosis, and management. Am J Health Syst Pharm 56: 961-976.
53. Latka MH, Hagan H, Kapadia F, Golub ET, Bonner S, Campbell J, Coady M, Garfein RS, Pu M, Thomas DL, Thiel T, Strathdee SA. 2008. A randomized intervention trial to reduce the lending of used injection equipment among injection drug users infected with hepatitis C. Am J Public Health 98: 853-861.
54. Lee MH, Yang HI, Lu SN, Jen CL, Yeh SH, Liu CJ, Chen PJ, You SL, Wang LY, Chen WJ, Chen CJ. 2010a. Hepatitis C virus seromarkers and subsequent risk of hepatocellular carcinoma: Long-term predictors from a community-based cohort study. J Clin Oncol 28: 4587-4593.
55. Lee Y-M, Lin H-J, Chen Y-J, Lee C-M, Wang S-F, Chang K-Y, Chen T-L, Liu H-F, Chen Y-MA. 2010b. Molecular epidemiology of HCV genotypes among injection drug users in Taiwan: Full-length sequences of two new subtype 6w strains and a recombinant form_2b6w. J Med Virol 82: 57-68.
56. Lehmann M, Meyer MF, Monazahian M, Tillmann HL, Manns MP, Wedemeyer H. 2004. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol 73: 387-391.
57. Lewis R, Billings D. 1997. Appalachian culture and economic development: A retrospective view on the theory and literature. J Appalachian Cult 3: 3-42.
58. Liao K-F, Lai S-W, Lin C-Y, Huang C-H, Lin Y-Y. 2011. Diversity of hepatitis C virus genotypes among intravenous heroin users in Taiwan. Am J Med Sci 341: 110-112.
59. Lopez-Labrador FX, Ampurdanes S, Forns X, Castells A, Saiz JC, Costa J, Bruix J, Sanchez Tapias JM, Jimenez de Anta MT, Rodes J. 1997. Hepatitis C virus (HCV) genotypes in Spanish patients with HCV infection: Relationship between HCV genotype 1b, cirrhosis and hepatocellular carcinoma. J Hepatol 27: 959-965.
60. Magiorkinis G, Magiorkinis E, Paraskevis D, Ho SYW, Shapiro B, Pybus OG, Allain J-P, Hatzakis A. 2009. The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis. PLoS Med 6: 1-12.
61. Mangia A, Cascavilla I, Lezzi G, Spirito F, Maertens G, Parlatore L, Saracco G, Rizzeto M, Andriulli A. 1997. HCV genotypes in patients with liver disease of different stages and severity. J Hepatol 26: 1173-1178.
62. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, Goodman ZD, Koury K, Mei-Hsiu L, Albrecht JK. 2001. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet 358: 958-965.
63. Manolakopoulos S, Deutsch M, Anagnostou O, Karatapanis S, Tiniakou E, Papatheodoridis G, Georgiou E, Manesis E, Tzourmakliotis D, Archimandritis A. 2010. Substitution treatment or active intravenous drug use should not be contraindications for antiviral treatment in drug users with chronic hepatitis C. Liver Int 2010: 10.
64. Martin NK, Vickerman P, Miners A, Foster GR, Hutchinson SJ, Goldberg DJ, Hickman M. 2012. Cost-effectiveness of hepatitis C virus antiviral treatment for injection drug user populations. Hepatology 55: 49-57.
65. McHutchison JG, Manns MP, Muir AJ, Terrault NA, Jacobson IM, Afdhal NH, Heathcote EJ, Zeuzem S, Reesink HW, Garg J, Bsharat M, George S, Kauffman RS, Adda N, Di Bisceglie AM. 2010. Telaprevir for previously treated chronic HCV infection. N Engl J Med 362: 1292-1303.
66. McMahon JM, Simm M, Milano D, Clatts M. 2004. Detection of hepatitis C virus in the nasal secretions of an intranasal drug-user. Ann Clin Microbiol Antimicrob 3: 6.
67. Mehta SH, Cox A, Hoover DR, Xiao-Hong W, Qing M, Ray S, Strathdee SA, Vlahov D, Thomas DL. 2002. Protection against persistence of hepatitis C. Lancet 359: 1478.
68. Micalessi MI, Gérard C, Ameye L, Plasschaert S, Brochier B, Vranckx R. 2008. Distribution of hepatitis C virus genotypes among injecting drug users in contact with treatment centers in Belgium, 2004-2005. J Med Virol 80: 640-645.
69. Mizokami M, Tanaka Y, Miyakawa Y. 2006. Spread times of hepatitis C virus estimated by the molecular clock differ among Japan, the United States, and Egypt in reflections of their distinct socioeconomic backgrounds. Intervirology 49: 28-36.
70. Munir S, Saleem S, Idrees M, Tariq A, Butt S, Rauff B, Hussain A, Badar S, Naudhani M, Fatima Z, Ali M, Ali L, Akram M, Aftab M, Khubaib B, Awan Z. 2010. Hepatitis C treatment: Current and future perspectives. Virol J 7: 296.
71. Nainan OV, Alter MJ, Kruszon-Moran D, Gao F-X, Xia G, McQuillan G, Margolis HS. 2006. Hepatitis C virus genotypes and viral concentrations in participants of a general population survey in the United States. Gastroenterology 131: 478-484.
72. National Digestive Diseases Information Clearinghouse. 2006. Chronic hepatitis C: Current disease management. NIH Publication No. 07-4230.
73. Nelson DR. 2011. The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naive patients. Liver Int 31: 53-57.
74. National Institutes of Health. 1997. Management of Hepatitis C. NIH Consens Statement 15:1-41.
75. National Institutes of Health. 2002. NIH Consensus Statement on Management of Hepatitis C: 2002. NIH Consens State Sci Statements 19: 1-46.
76. Obermeier M, Inqiliz P, Weitner L, Cordes C, Moll A, Hinsche B, Schlote F, Koeppe S, Christensen S, Mayr C, Baumgarten A. 2011. Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV): The "real-life setting" proves the concept. Eur J Med Res 16: 237-242.
77. O'Brien J, Kruzel K, Wandell M, Vinogradov I, Sheagren J, Frank A. 2001. Detection of Hepatitis C antibody with at-home collection kits using an innovative laboratory algorithm. Infect Dis Clin Pract 10: 474-480.
78. Operskalski EA, Mack WJ, Strickler HD, French AL, Augenbraun M, Tien PC, Villacres MC, Spencer LY, Degiacomo M, Kovacs A. 2008. Factors associated with hepatitis C viremia in a large cohort of HIV-infected and -uninfected women. J Clin Virol 41: 255-263.
79. Panduro A, Roman S, Khan A, Tanaka Y, Kurbanov F, Martinez-Lopez E, Campollo O, Hernandez-Nazara Z, Mizokami M. 2010. Molecular epidemiology of hepatitis C virus genotypes in West Mexico. Virus Res 151: 19-25.
80. Papadopoulos V, Gogou A, Mylopoulou T, Mimidis K. 2010. Should active injection drug users receive treatment for chronic hepatitis C? Arq Gastroenterol 47: 238-241.
81. Pawlotsky JM. 2011. The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: A new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 140: 746-754.
82. Photiadis J, Schwarzweller H. editors. 1970. Change in rural appalachia: Implications for action programs. Philadelphia: University of Pennsylvania Press.
83. Poordad F, McCone J, Jr., Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP. 2011. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195-1206.
84. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, Bain V, Heathcote J, Zeuzem S, Trepo C, Albrecht J. 1998. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352: 1426-1432.
85. Pybus OG, Charleston MA, Gupta S, Rambaut A, Holmes EC, Harvey PH. 2001. The epidemic behavior of the hepatitis C virus. Science 292: 2323-2325.
86. Raimondi S, Bruno S, Mondelli MU, Maisonneuve P. 2009. Hepatitis C virus genotype 1b as a risk factor for hepatocellular carcinoma development: A meta-analysis. J Hepatol 50: 1142-1154.
87. Reid AE, Koziel MJ, Aiza I, Jeffers L, Reddy R, Schiff E, Lau JY, Dienstag JL, Liang TJ. 1999. Hepatitis C virus genotypes and viremia and hepatocellular carcinoma in the United States. Am J Gastroenterol 94: 1619-1626.
88. Romeo R, Colombo M, Rumi M, Soffredini R, Del Ninno E, Donato MF, Russo A, Simmonds P. 1996. Lack of association between type of hepatitis C virus, serum load and severity of liver disease. J Viral Hepat 3: 183-190.
89. Ryu SH, Fan X, Xu Y, Elbaz T, Zekri AR, Abdelazziz AO, Di Bisceglie AM. 2009. Lack of association between genotypes and subtypes of HCV and occurrence of hepatocellular carcinoma in Egypt. J Med Virol 81: 844-847.
90. Sacks-Davis R, Horyniak D, Grebely J, Hellard M. 2012. Behavioural interventions for preventing hepatitis C infection in people who inject drugs: A global systematic review. Int J Drug Policy 23: 176-184.
91. Salomon J, Weinstein M, Hammitt J, Goldie S. 2003. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 290: 228-237.
92. Substance Abuse and Mental Health Administration. 2008. 2007 National survey on drug use and health: National results. Rockville, MD: Office of Applied Studies.
93. Sangiovanni A, Iavarone M. 2008. Hepatitis C virus genotype 1b, cirrhosis, and risk of hepatocellular carcinoma. Hepatology 47: 357.
94. Sartori M, Andorno S, Avogadro E, Ballare M, La Terra G, Leone F, Quaglia V, Fortina G, Aglietta M. 1996. High prevalence of hepatitis C virus (HCV) genotype 2 in Italian patients with chronic liver disease. Ital J Gastroenterol 28: 452-456.
95. Schulte B, Schütt S, Brack J, Isernhagen K, Deibler P, Dilg C, Verthein U, Haasen C, Reimer J. 2010. Successful treatment of chronic hepatitis C virus infection in severely opioid-dependent patients under heroin maintenance. Drug Alcohol Depend 109: 248-251.
96. Scott LJ, Perry CM. 2002. Interferon-alpha-2b plus ribavirin: A review of its use in the management of chronic hepatitis C. Drugs 62: 507-556.
97. Sereno S, Perinelli P, Laghi V. 2009. Changes in the prevalence of hepatitis C virus genotype among Italian injection drug users: Relation to period of injection started. J Clin Virol 45: 354-357.
98. Serra MA, Rodríguez F, del Olmo JA, Escudero A, Rodrigo JM. 2003. Influence of age and date of infection on distribution of hepatitis C virus genotypes and fibrosis stage. J Viral Hepat 10: 183-188.
99. Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J. 2004. Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess 8: 1-125.
100. Shepherd J, Jones J, Hartwell D, Davidson P, Price A, Waugh N. 2007. Interferon alpha (pegylated and non-pegylated) and ribavirin for the treatment of mild chronic hepatitis C: A systematic review and economic evaluation. Health Technol Assess 11: 1-205.
101. Sjogren M, Sjogren RJ, Lyons M, Ryan M, Santoro J, Smith C, Reddy K, Bonkovsky H, Huntley B, Faris-Young S. 2007. Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin. Dig Dis Sci 52: 1540-1547.
102. Spada E, Abbate I, Sicurezza E, Mariano A, Parla V, Rinnone S, Cuccia M, Capobianchi MR, Mele A. 2008. Molecular epidemiology of a hepatitis C virus outbreak in a hemodialysis unit in Italy. J Med Virol 80: 261-267.
103. Stern RK, Hagan H, Lelutiu-Weinberger C, Jarlais DD, Scheinmann R, Strauss S, Pouget ER, Flom P. 2008. The HCV synthesis project: Scope, methodology, and preliminary results. BMC Med Res Methodol 8: 62.
104. Strasfeld L, Lo Y, Netski D, Thomas DL, Klein RS. 2003. The association of hepatitis C prevalence, activity, and genotype with HIV infection in a cohort of New York City drug users. J Acquir Immune Defic Syndr 33: 356-364.
105. Su J, Brook R, Kleinman N, Corey-Lisle P. 2010. The impact of hepatitis C virus infection on work absence, productivity, and healthcare benefit costs. Hepatology 52: 436-442.
106. Sullivan S, Jensen D, Bernstein D, Hassanein T, Foster G, Lee S, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Pettit K, Patel K, Green J. 2004. Cost-effectiveness of combination peginterferon alpha-2a and ribavirin compared with interferon alpha-2b and ribavirin in patients with chronic hepatitis C. Am J Gastroenterol 99: 1490-1496.
107. Swan D, Long J, Carr O, Flanagan J, Irish H, Keating S, Keaveney M, Lambert J, McCormick PA, McKiernan S, Moloney J, Perry N, Cullen W. 2010. Barriers to and facilitators of hepatitis C testing, management, and treatment among current and former injecting drug users: A qualitative exploration. AIDS Patient Care STDs 24: 753-762.
108. Tanaka K, Hirohata T. 1998. Relationship of hepatitis C virus genotypes and viremia levels with development of hepatocellular carcinoma among Japanese. Fukuoka Igaku Zasshi 89: 238-248.
109. Tanaka Y, Hanada K, Mizokami M, Yeo A, Shih JW, Gojobori T, Alter HJ. 2002. A comparison of the molecular clock of hepatitis C virus in the United States and Japan predicts that hepatocellular carcinoma incidence in the United States will increase over the next two decades. Proc Natl Acad Sci 99: 15584-15589.
110. Thomas DL, Seeff LB. 2005. Natural history of hepatitis C. Clin Liver Dis 9: 383.
111. Thomas DL, Astemborski J, Rai RM, Anania FA, Schaeffer M, Galai N, Bolt K, Nelson KE, Strathdee SA, Johnson L, Laeyendecker O, Boitnott J, Wilson LE, Vlahov D. 2000. The natural history of hepatitis C virus infection: Host, viral, and environmental factors. JAMA 284: 450-456.
112. Tsai JF, Chang WY, Jeng JE, Ho MS, Lin ZY, Tsai JH. 1994. Effects of hepatitis C and B viruses infection on the development of hepatocellular carcinoma. J Med Virol 44: 92-95.
113. van den Berg C, Smit C, van Brussel G, Coutinho R, Prins M. 2007. Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: Evidence from the Amsterdam Cohort Studies among drug users. Addiction 102: 1454-1462.
114. van den Berg CH, van de Laar TJ, Kok A, Zuure FR, Coutinho RA, Prins M. 2009. Never injected, but hepatitis C virus-infected: a study among self-declared never-injecting drug users from the Amsterdam cohort studies. J Viral Hepat 16: 568-577.
115. Viazov S, Ross SS, Kyuregyan KK, Timm J, Neumann-Haefelin C, Isaeva OV, Popova OE, Dmitriev PN, El Sharkawi F, Thimme R, Michailov MI, Roggendorf M. 2010. Hepatitis C virus recombinants are rare even among intravenous drug users. J Med Virol 82: 232-238.
116. Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. 1999. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 29: 908-914.
117. Wang J, Falk RS, Li L, Rahman A, Carlson RG. 2007. Respondent-driven sampling in the recruitment of illicit stimulant drug users in a rural setting: Findings and technical issues. Addict Behav 32: 924-937.
118. Whisnant D. 1980. Modernizing the mountaineer: People, power, and planning in Appalachia. Boone, NC: Appalachian Consortium Press.
119. Widell A, Verbaan H, Wejstal R, Kaczynski J, Kidd-Ljunggren K, Wallerstedt S. 2000. Hepatocellular carcinoma in Sweden: Its association with viral hepatitis, especially with hepatitis C viral genotypes. Scand J Infect Dis 32: 147-152.
120. Witthöft T. 2008. Review of consensus interferon in the treatment of chronic hepatitis C. Biologics 2: 635-643.
121. Witthöft T, Fuchs M, Ludwig D. 2007. Recent i.v.-drug users with chronic hepatitis C can be efficiently treated with daily high dose induction therapy using consensus interferon: An open-label pilot study. World J Gastroenterol 28: 579-584.
122. Wong J, Bennett W, Koff R, Pauker S. 1998. Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs. JAMA 280: 2088-2093.
123. Yeh W, Armstrong E, Skrepnek G, Malone D. 2007. Peginterferon alfa-2a versus peginterferon alfa-2b as initial treatment of hepatitis C virus infection: A cost-utility analysis from the perspective of the Veterans affairs health care system. Pharmacotherapy 27: 813-824.
124. Young AM, Havens JR. 2012. Transition from first illicit drug use to first injection drug use among rural Appalachian drug users: A cross-sectional comparison and retrospective survival analysis. Addiction 107: 587-596.
125. Young AM, Havens JR, Leukefeld CG. 2010. Route of administration for illicit prescription opioids: A comparison of rural and urban drug users. Harm Reduct J 7: 24.
126. Young AM, Havens JR, Leukefeld CG. 2012. A comparison of rural and urban nonmedical prescription opioid users' lifetime and recent drug use. Am J Drug Alcohol Abuse 38: 220-227.
127. Zein NN. 2000. Clinical significance of hepatitis C virus genotypes. Clin Microbiol Rev 13: 223-235.
128. Zein NN, Rakela J, Krawitt EL, Reddy KR, Tominaga T, Persing DH. 1996. Hepatitis C virus genotypes in the United States: Epidemiology, pathogenicity, and response to interferon therapy. Collaborative Study Group. Ann Intern Med 125: 634-639.
129. Zekri AR, Bahnassy AA, Shaarawy SM, Mansour OA, Maduar MA, Khaled HM, El-Ahmadi O. 2000. Hepatitis C virus genotyping in relation to neu-oncoprotein overexpression and the development of hepatocellular carcinoma. J Med Microbiol 49: 89-95.
130. Zeuzem S, Teuber G, Lee JH, Rüster B, Roth WK. 1996. Risk factors for the transmission of hepatitis C. J Hepatol 24: 3-10.
131. Zhou Y, Wang X, Mao Q, Fan Y, Zhu Y, Zhang X, Lan L, Jiang L, Tan W. 2009. Changes in modes of hepatitis C infection acquisition and genotypes in southwest China. J Clin Virol 46: 230-233.